Sweden · Delayed Price · Currency is SEK Camurus AB Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw strong revenue and profit growth, driven by Brixadi royalties and Buvidal expansion, despite FX headwinds and a UK distribution change. Regulatory milestones included Oczyesa approval and launch, while R&D advanced with positive CAM2056 results. 2026 guidance anticipates continued double-digit growth and increased investment in U.S. operations.
-
The session highlighted strong clinical progress for once-monthly semaglutide and long-acting octreotide, robust commercial growth for opioid use disorder treatments, and a strategic partnership with Eli Lilly. Despite a 2025 outlook downgrade, profit guidance is maintained and future growth is expected from new launches and partnerships.
-
Q3 2025 saw strong profitability, 18% revenue growth year-on-year, and robust cash flow, but full-year revenue guidance was lowered due to U.S. and U.K. headwinds. Product launches and pipeline progress continued, with Oczyesa launched in Germany and Brixadi gaining U.S. market share.
-
Record Q2 revenues and profitability driven by Buvidal and Brixadi growth, EU approval of Oxyceisa, and a major licensing deal with Eli Lilly. Strong cash position and maintained guidance, with further growth expected in H2 as funding and access improve.
-
A major partnership with Eli Lilly validates the FluidCrystal platform, while Brixadi and Buvidal continue to expand globally despite temporary Medicaid headwinds. CAM2029 and CAM2056 advance in late-stage trials, supporting a confident outlook for 40%-50% revenue growth in 2024.
-
Q1 2025 saw record profitability, 43% revenue growth, and strong Buvidal expansion in Europe and Australia. Brixadi U.S. royalties surged 185% year-over-year despite a 13% market decline, and regulatory progress for CAM2029 in acromegaly continues in the EU and U.S.
Fiscal Year 2024
-
Strong revenue and profit growth in 2024 driven by Buvidal and Brixadi, with robust cash position and no debt. Regulatory progress and new launches are expected to fuel 2025 growth, while manufacturing expansion and R&D investments support long-term targets.
-
Strong progress toward 2027 targets with raised guidance and expanding product uptake in key markets. Regulatory milestones for CAM2029 and new pipeline advances are expected in 2025, while commercial opportunities in opioid use disorder and rare diseases remain robust.
-
Q3 saw revenue rise to SEK 480 million and profit before tax up 125% year-over-year, driven by strong Buvidal and Brixadi sales. Guidance for 2024 was raised, with robust cash reserves and continued R&D progress, despite regulatory delays for CAM2029.
-
Q2 2024 saw 46% year-over-year revenue growth (excluding one-time items), strong Buvidal and Brixadi sales, and a gross margin of 92.9%. R&D and pipeline advances continued, with guidance reiterated for the year.
-
Strong commercial growth in opioid dependence treatments is driving robust financials and market expansion, with major pipeline milestones ahead. CAM2029 is on track for U.S. approval and launch, while new GLP-1 candidates and GEP-NET data are expected in 2025.